Jia Liu – CEO, DreamCIS, South Korea
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
Address: 1010, 10F, Jeokseon Hyundai Bld, 80, Jeokseon-dong, Seoul, Jongno-gu, Seoul,Republic of Korea
Tel: +82 2 2010 4500
DreamCIS is a full service contract research organization (CRO) that offers to the pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. DreamCIS provides clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard operating procedures consistent with both Republic of Korean regulations and global standards including ICH-GCP guidelines. DreamCIS aims at enhancing both the reliability of its clinical services provided and product competitiveness by striving to maintain the consistency in quality of its services. Accomplishing this goal will no doubt enable us to contribute to the health of the people. DreamCIS has its Specialist Advisory Committee comprised of high-level specialists in their field to provide comprehensive and specialized clinical services. The community in partnership with DreamCIS include Ionet Republic of Korea which was organized by DreamCIS exclusively for the development of Web-CRF program, DreamCIS’s patented product, Yonsei University Department of Biostatics Medical College, YOU & ME Patent and Law Firm, Yonsei University Research Institute of Food & Nutrition, SMSI (Seoul Medical Science Institute), Biotoxtech Co.,Ltd. DreamCIS has launched a business partnership with Gleneagles CRC (Singapore), a leading CRO/SMO in the Asia Pacific region, with the aim to conduct multi-national clinical trials seamlessly for multi-national customers as well. Founded in April, 2000, DreamCIS has ever since been dedicated to providing a full range of clinical services for a number of customers/sponsors, including major pharmaceutical companies, multi-national pharmaceutical companies, bio venture companies, health food producers, and medical device manufacturers in Republic of Korea. DreamCIS will continue striving to provide customers reliable clinical trial data while conducting all of clinical trials using our expertise and significant experience in the field of clinical trials.
It aims to provide customers differentiated services based on strict quality control in a scientific and systematic manner and high ethical standards. DreamCIS’ key service areas include: ㆍClinical trials for medicines / medical devices ㆍPost-marketing surveillance (PMS) ㆍQA audit ㆍData management and Statistical analysis ㆍHealth functional foods Trials ㆍPre-clinical trials management ㆍTraining and dispatch of clinical research nurses
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
